Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved patient groups.

CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD) ↗

April 25, 2026

Performance

52-Week Range

14.49

7.6852W Low 14.4952W High

Amicus Therapeutics, Inc. - Common Stock (FOLD) traded between $7.68 and $14.49 over the past 52 weeks and last traded at $14.49.

Past 12 Months

N/A

+0.3%

+1.5%

+87.9%

6M +$0.05

YTD +$0.22

1Y +$6.78

FOLD was +87.9% over the past year, +0.3% over six months, +1.5% year to date.

12 Months vs Market

FOLD

+87.9%

DIA

+10.0%

SPY

+15.1%

QQQ

+24.3%

IWM

+16.1%

Over the past 12 months FOLD returned +87.9% versus DIA (Dow) +10.0%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +16.1%.

Volume & Liquidity

2.5M

YTD

5.6M

7.1M

More News

Rice Hall James Buys QuidelOrtho Stock ↗

March 09, 2026

Rice Hall James Buys Stride Stock ↗

March 09, 2026

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

February 20, 2026

From Amicus Therapeutics, Inc.

Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders

February 19, 2026

Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026

February 03, 2026

From Amicus Therapeutics, Inc.

Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm’s Investigations

February 02, 2026

Should You Buy BioMarin Pharmaceutical Before Feb. 18? ↗

January 31, 2026

FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

January 23, 2026

Halper Sadeh LLC Encourages PEN, FOLD, DBRG, FFIC Shareholders to Contact the Firm to Discuss Their Rights

Via Business Wire

January 22, 2026

Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights

January 07, 2026

The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity

January 06, 2026

Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights

January 06, 2026

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

December 26, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

The Liquidity Vacuum: Thin Holiday Trading Sparks Volatility as 2025 Draws to a Close

December 26, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq

December 23, 2025

From Brodsky & Smith LLC

Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights

Unusual volume stocks in Tuesday's session ↗

December 23, 2025

Via Chartmill

December 20, 2025